Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 3Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia 2Waldenstrom Macroglobulinemia 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Prolymphocytic 1

Interventions

fludarabine phosphate 52Cyclophosphamide 52Peripheral Blood Stem Cell Transplantation 50Rituximab 47Mycophenolic Acid 34Whole-Body Irradiation 33Tacrolimus 26Cyclosporine 25Busulfan 23Etoposide 21Filgrastim 19Methotrexate 18Melphalan 18Antilymphocyte Serum 18Radiotherapy 15Bortezomib 15Sirolimus 12Lenalidomide 11ibrutinib 9Flow Cytometry 9Cyclosporins 9Everolimus 8Dexamethasone 8Carboplatin 8sargramostim 7Polymerase Chain Reaction 7Methylprednisolone 7Indium 7Cytarabine 7idelalisib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Waldenstrom Macroglobulinemia × Immunization, Passive × Other hematologic neoplasm × Clear all
NCT00265928 2008-01-28

Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

National Cancer Institute (NCI)

Phase 2 Terminated
46 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡